Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811314 | 0.97 | CES2 (0.68) | — | |
| SCHEMBL24446 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL753936 | 0.95 | — | — | |
| SCHEMBL9580893 | 0.95 | CES2 (0.65) | — | |
| Cesium SCHEMBL30912038 | 0.95 | — | — | |
| SCHEMBL25196785 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL6719610 | 0.95 | — | — | |
| SCHEMBL25212901 | 0.95 | — | — | |
| SCHEMBL3467845 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL30994934 | 0.95 | CES2 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103269687-A | Bepotastine compositions | ISTA PHARMACEUTICALS INC | 2013-08-28 | — | — | CN | claimed |
| CN-102499928-A | Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid | SCHERING PLOUGH LTD | 2012-06-20 | — | — | CN | claimed |
| JP-4792032-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| CN-102202713-A | Light blocking container with viewing window for photosensitive compounds | SCHERING CORP | 2011-09-28 | — | — | CN | claimed |
| CN-102202979-A | Light blocking container with content viewing window and contrast background | SCHERING CORP | 2011-09-28 | — | — | CN | claimed |
| CN-102036655-A | Method for minimizing polymorphism | SCHERER TECHNOLOGIES INC R P | 2011-04-27 | — | — | CN | claimed |
| CN-101443018-A | Sterilized nanoparticulate glucocorticosteroid formulations | ELAN PHARMA INT LTD (IE) | 2009-05-27 | — | — | CN | claimed |
| EP-1776109-B1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | SCHERING PLOUGH LTD (CH) | 2008-12-31 | — | — | EP | claimed |
| CN-101180038-A | Nanoparticulate corticosteroid and antihistamine formulations | ELAN PHARMA INT LTD (IE) | 2008-05-14 | — | — | CN | claimed |
| CN-101039668-A | Pharmaceutical formulations comprising an antibiotic, a triazole and a corticosteroid | SCHERING PLOUGH LTD (CH) | 2007-09-19 | — | — | CN | claimed |
| EP-1776109-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | Schering-Plough Ltd. (CH) | 2007-04-25 | — | — | EP | claimed |
| WO-2006020689-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | SCHERING-PLOUGH LTD. (CH) | 2006-02-23 | — | — | WO | claimed |
| US-6956030-B2 | Use of mometasone furoate for treating upper airway diseases | SCHERING CORPORATION (US) | 2005-10-18 | — | — | US | claimed |
| WO-2005089171-A2 | PROTOCOL FOR IMPROVING VISION | MULLALLY JOHN P (US) | 2005-09-29 | — | — | WO | claimed |
| US-20040192660-A1 | Protocol for improving vision | MULLALLY JOHN P (US) | 2004-09-30 | — | — | US | claimed |
| WO-2004080414-A2 | COMPOSITION AND METHOD FOR TREATING INFLAMMATIONS BY REDUCING C-REACTIVE PROTEIN | MULLALLY JOHN P (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040180868-A1 | Composition and method for treating inflammations by reducing C-reactive protein | MULLALLY JOHN P (US) | 2004-09-16 | — | — | US | claimed |
| EP-4696353-A2 | NASAL DRUG DELIVERY APPARATUS | Pneuma Respiratory, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-0217748-B1 | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof | CIBA-GEIGY AG (CH) | 1991-02-06 | — | — | EP | disclosed |
| EP-0217748-A2 | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof | CIBA-GEIGY AG (CH) | 1987-04-08 | — | — | EP | disclosed |